No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for NewcelX Ltd. (NCEL) stock was $3.09 as of Oct 6, 2026, 11:47 AM EDT, up 8.04% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -85.6% · 3-year avg -78.7%/yr · 5-year avg -69.0%/yr
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Biotechnology · Kloten, ZH
Next Earnings Date
Mar 3, 2027
148 days away
EPS Estimate
-0.65
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.53
vs Estimate
$-0.53
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NCEL | $1.39M | $3.09 | +8.04% | -85.57% | -68.96% | N/A | N/A |
| 2ARTL | $1.40M | $3.61 | +2.85% | -91.59% | -64.27% | N/A | vs NCEL |
| 3NXGL | $1.40M | $0.17 | -2.82% | -93.27% | N/A | N/A | vs NCEL |
| 4GNPX | $1.37M | $2.72 | +0.00% | -98.68% | -88.16% | N/A | vs NCEL |
| 5IVF | $1.45M | $0.81 | -2.38% | -97.33% | -90.41% | -69.30% | vs NCEL |
| 6ELAB | $1.47M | $3.24 | -0.92% | -99.94% | N/A | N/A | vs NCEL |
N/A
Consensus Rating
Based on 1 analyst
Average Price Target
$23.00
+644.4% upside
Low
$23.00
Current
$3.09
High
$23.00
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.18 | $-1.18 | $-1.18 | 1 |
| FY 2027 | $-0.60 | $-0.60 | $-0.60 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $132.52M | $132.52M | $132.52M | 1 |
| FY 2027 | $178.62M | $178.62M | $178.62M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
